User:Mr. Ibrahem/Selexipag

Selexipag, sold under the brand name Uptravi, is a medication used to treat pulmonary arterial hypertension (PAH). Generally it is used in people in who an endothelin receptor antagonist and PDE5 inhibitor are not enough. It is taken by mouth or injection into a vein.

Common side effects include headache, diarrhea, muscle pain, flushing, and rash. Other side effects can include pulmonary edema. It should not be used in people with significant coronary artery disease or valvular heart disease. It works by activating the prostacyclin receptor which causes the muscles in blood vessels to relax.

Selexipag was approved for medical use in the United States in 2015 and Europe in 2016. In the United States it costs about 20,100 USD a month as of 2021. In the United Kingdom this amount costs the NHS about £3,000.